NCT07210320View on ClinicalTrials.gov

PK/PD Study of IN-001 Sublingual Spray in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 24, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Type 1 AllergyAnaphylaxis
Interventions
DRUG

Epinephrine Auto-Injector 0.3 mg/0.3 mL

Epinephrine injection

DRUG

Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle

Epinephrine injection

DRUG

IN-001 9.06 mg Sublingual Spray

Sublingual Spray

DRUG

IN-001 13.59 mg Sublingual Spray

Sublingual Spray

Trial Locations (1)

63110

RECRUITING

Washington University in St. Louis School of Medicine, St Louis

Sponsors
All Listed Sponsors
collaborator

Washington University School of Medicine

OTHER

lead

Insignis Therapeutics, Inc.

INDUSTRY

NCT07210320 - PK/PD Study of IN-001 Sublingual Spray in Healthy Adults | Biotech Hunter | Biotech Hunter